Update on the role of lenalidomide in patients with multiple myeloma

Therapeutic Advances in Hematology
Sarah A HolsteinPhilip L McCarthy

Abstract

Lenalidomide is a derivative of thalidomide and belongs to the class of drugs known as the immunomodulatory drugs (IMiDs). The IMiDs have played a large role in improving the survival outcomes of patients with multiple myeloma. In particular, lenalidomide is currently standard of care in the newly diagnosed setting, in the maintenance setting post-autologous stem cell transplant, as well as in the relapsed/refractory setting. While the combination of lenalidomide and various proteasome inhibitors has proven particularly effective, there are emerging data demonstrating the effectiveness of lenalidomide in combination with other important classes of drugs including the monoclonal antibodies. Recent studies have provided insight into the molecular target of lenalidomide and the other IMiDs, although there is still much to be learned regarding the mechanisms by which lenalidomide affects the myeloma cell and the immune system. Here we review the molecular mechanisms of action, side effects, and the results of the clinical trials which have led to the widespread incorporation of lenalidomide into the myeloma therapeutic armamentarium.

References

Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francisco J Hernandez-IlizaliturriMyron S Czuczman
Sep 19, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R BazM A Hussein
Mar 24, 2007·Molecular Biology Reports·Wang XinWu Qihan
Jun 26, 2007·Molecular Cell·Jennifer Lee, Pengbo Zhou
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboUNKNOWN GIMEMA--Italian Multiple Myeloma Network
Nov 2, 2007·Leukemia·K C AndersonUNKNOWN ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Nov 15, 2008·Cancer Immunology, Immunotherapy : CII·Christine GalustianAngus G Dalgleish
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonKenneth C Anderson
Mar 13, 2010·Science·Takumi ItoHiroshi Handa
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher M Booth, Elizabeth A Eisenhauer
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sagar LonialSundar Jagannath
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Mar 1, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruben NiesvizkyMichael Wang
Oct 17, 2013·Leukemia Research·Steven R SchusterA Keith Stewart

❮ Previous
Next ❯

Citations

Oct 1, 2019·Current Opinion in Hematology·Taewoong Choi
Sep 12, 2020·Journal of Clinical Medicine·Catalin ConstantinescuCiprian Tomuleasa
Mar 4, 2020·International Journal of Oncology·Romina Gabriela ArmandoDaniel Eduardo Gomez
Sep 23, 2020·BMJ : British Medical Journal·Urvi A Shah, Sham Mailankody
Sep 13, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel W SherbenouBin Liu
Sep 26, 2020·Blood Reviews·Christina PohAaron Seth Rosenberg
Oct 29, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zachary J WalkerDaniel W Sherbenou
Dec 15, 2018·International Immunopharmacology·Nayoung KimHun Sik Kim
May 7, 2021·Alzheimer's Research & Therapy·Antonio AncidoniMarco Canevelli
Jul 3, 2021·Frontiers in Oncology·Gregorio BarilàRenato Zambello

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
GTPase
flow cytometry

Clinical Trials Mentioned

NCT01863550
NCT03290950
NCT03012880
NCT02874742
NCT03319667
NCT03104842
NCT02375555
NCT02252172
NCT01850524

Related Concepts